Use of anagrelide for treating cancer
The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.
1. A method of treating metastatic disease, comprising administering to a human thrombocytotic cancer patient in need thereof a therapeutic amount of a compound;
wherein the human thrombocytotic cancer patient has a primary cancer;
the site of the metastatic disease is a bone or lung of the human thrombocytotic cancer patient;
the compound inhibits migratory attraction of circulating cancer cells towards megakaryocytes found at the bone or lung of the human thrombocytotic cancer patient; and
the compound is anagrelide, or a pharmaceutically acceptable salt, solvate or active metabolite thereof, wherein the active metabolite of anagrelide is anagrelide that has been hydroxylated at position 5, 8 or 9, oxidized at the tertiary nitrogen position forming an N-oxide, or a combination thereof.
2. The method of claim 1 , wherein the compound is formulated as a formulation selected from the group consisting of sublingual tablets, buccal spray, mucoadhesive buccal tablets, mucoadhesive buccal films, buccal lozenges, buccal lollipops, rectal suppositories, rectal gels, nasal spray, pulmonary delivery devices, transdermal patches, transdermal gels, transdermal ointment, transdermal creams, and injectable formulations.
3. The method of claim 1 , wherein the human thrombocytotic patient has a platelet count that is reduced to an upper limit of 400×103/μL but above a lower limit of 150×103/μL.
4. The method of claim 1 , wherein the human thrombocytotic patient has a platelet count that is reduced to an upper limit of 350×103/μL but above a lower limit of 150×103/μL.
5. The method of claim 1 , wherein the human thrombocytotic patient has a platelet count that is reduced to an upper limit of 300×103/μL, but above a lower limit of 150×103/μL.
6. The method of claim 1 , wherein the human thrombocytotic patient has a platelet count that is reduced to an upper limit of 250×103/μL, but above a lower limit of 150×103/μL.
7. The method of claim 2 , wherein the formulation is an injectable formulation; and the is formulated for intravenous, intramuscular, or subcutaneous administration.
8. The method of claim 1 , wherein the primary cancer is a cancer of the brain, a cancer of the oral cavity, a cancer of the head and neck, thyroid carcinoma, gastrointestinal cancers, pancreatic cancer, hepatocellular cancer, colorectal cancer, cancer of the lungs, cancer of the ovaries, a cancer of the endometrium, a cancer of the cervix, breast cancer, prostate cancer, a cancer of the kidneys, skin mesothelioma, melanoma, a cancer of the gallbladder, or multiple myeloma.
9. The method of claim 1 , wherein the primary cancer is a cancer of the lungs, a cancer of the ovaries, a cancer of the kidneys, or a colorectal cancer.
10. The method of claim 1 , wherein the primary cancer is a cancer of the lungs.
11. The method of claim 1 , wherein the primary cancer is a cancer of the ovaries.
12. The method of claim 1 , wherein the primary cancer is a cancer of the kidneys.
13. The method of claim 1 , wherein the primary cancer is a colorectal cancer.